Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycopene + soy isoflavone is a combination dietary supplement investigated for its potential benefits in metabolic health and glucose regulation. Lycopene is a potent antioxidant carotenoid primarily derived from tomatoes, while soy isoflavones (such as genistein and daidzein) are phytoestrogens known to modulate lipid and glucose metabolism. The specific formulation Laflavon, developed by CamMedica, is designed to enhance the bioavailability of these components, containing 7 mg of lycopene and 50 mg of soy isoflavones. Clinical research, including trials sponsored by the University of Texas Medical Branch, has focused on the combination's ability to improve glucose tolerance, reduce insulin resistance, and lower HbA1c levels in patients with metabolic syndrome or mild Type 2 diabetes mellitus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycopene + soy isoflavone.